Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study
| العنوان: | Characterization and Outcomes in Patients Treated With Apremilast in Routine Clinical Practice in Spain: Results From the APPRECIATE Study |
|---|---|
| المؤلفون: | M. Cordey, M. Serra, J. Mataix Díaz, A. Mateu, Ricardo Ruiz-Villaverde, Enrique Herrera-Acosta, J. Tercedor-Sánchez, Pedro Herranz, E. Martínez, O. Baniandrés, L. Trasobares, Catalina Arenas García, N. Rivera, N. Jiménez-Gómez, D.P. Ruiz Genao |
| المصدر: | Actas Dermo-Sifiliograficas r-FISABIO. Repositorio Institucional de Producción Científica instname r-FISABIO: Repositorio Institucional de Producción Científica Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana (FISABIO) |
| بيانات النشر: | ELSEVIER ESPANA S I, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | medicine.medical_specialty, Histology, business.industry, Dermatology, Dermatology Life Quality Index, Clinical practice, medicine.disease, Pathology and Forensic Medicine, Clinical trial, Therapeutic benefits, Tolerability, Quality of life, Psoriasis Area and Severity Index, Internal medicine, Psoriasis, Medicine, Apremilast, business, Adverse effect, medicine.drug |
| الوصف: | Background and objectives: It is necessary to expand the knowledge in the use of apremilast in clinical practice. The APPRECIATE study (NCT02740218) aims to describe the characteristics of patients with psoriasis treated with apremilast, to evaluate their perspectives and those of dermatologists, as well as the outcomes obtained in clinical practice in Spain. Methods: Observational, retrospective, cross-sectional, multicenter study of patients with chronic plaque psoriasis who could be contacted 6 (+/- 1) months after apremilast initiation. The data were obtained from medical records and questionnaires from patients and physicians. Results: A total of 80 patients were evaluated; at apremilast onset, they showed mean (standard deviation, SD) Psoriasis Area and Severity Index (PASI) = 8.3 (5.3), mean (SD) Dermatology Life Quality Index (DLQI) = 8.9 (6.6). At six months, 58.8% (n=47) of patients continued apremilast treatment (discontinuations due to lack of efficacy [16.3%], safety/tolerability [20.0%]). In patients continuing treatment, PASI75 was achieved by 36.7% of patients; mean (95% CI) DLQI score was 2.2 (0.7-3.6) and mean (SD) Patient Benefit Index score was 2.8 (0.8). Compliance with physicians' expectations was correlated with benefits reported by patients (r=0.636). Adverse events were reported by 56.3% of patients (the most common were diarrhoea and nausea). Conclusions: Patients receiving apremilast for 6 months in Spanish clinical practice, reported substantial improvements in their quality of life (mean DLQI reduced by more than 6 points) and disease severity (PASI75 achieved by over one-third of patients), despite less skin involvement than patients who enrolled in clinical trials. (C) 2021 AEDV. Published by Elsevier Espana, S.L.U. |
| تدمد: | 0001-7310 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52a0e6829f420dac8daee74f5bd9744e https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=9936 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....52a0e6829f420dac8daee74f5bd9744e |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 00017310 |
|---|